---
layout: default
title: Ropivacaine
parent: 僅模型預測 (L5)
nav_order: 1135
evidence_level: L5
indication_count: 4
---

# Ropivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine: From Regional Anesthesia to Migraine Disorder

## One-Sentence Summary

> Ropivacaine is an amide-type local anesthetic conventionally used for regional and local nerve block anesthesia and postoperative pain control.
> The TxGNN model predicts it may be effective for **Migraine Disorder** (via nerve block procedures such as sphenopalatine and stellate ganglion block),
> with **4 clinical trials** and **6 publications** currently supporting this direction — though evidence quality is mixed and largely procedural rather than pharmacological.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Local/regional anesthesia (based on known drug class; official approved indication text not available — Data Gap DG001) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (Data Gap DG002). Based on established pharmacology, ropivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels to inhibit neural conduction. It is well established as a regional/local anesthetic agent, commonly delivered via nerve block, epidural, or infiltration techniques.

The mechanistic rationale for migraine is that sodium-channel blockade, when applied at specific anatomical targets — the sphenopalatine ganglion (SPG), stellate ganglion, or paraspinal/trigger-point regions — can interrupt trigeminovascular signaling and central sensitization pathways implicated in migraine pathogenesis. This is a biologically plausible mechanism supported by multiple procedural studies.

However, this repurposing candidate differs from a typical systemic-drug repurposing case: the evidence here evaluates ropivacaine as **part of an interventional nerve-block procedure**, not as a standalone pharmacotherapy. The rationale for the second predicted indication (migraine with brainstem aura) explicitly notes that its only supporting literature is a case report of an adverse event (Horner's syndrome), not a treatment result, and should not be considered mechanistic support. Efficacy attribution therefore needs to be evaluated together with procedural technique, not drug pharmacology alone.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | RCT of sphenopalatine ganglion (SPG) block with local anesthetic vs. placebo for migraine prevention; directly targets migraine population but severely underpowered (n=10) |
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | N/A | Completed | 150 | Paraspinal intramuscular ropivacaine injection evaluated for pediatric headache in an emergency department; broader headache population, not adult migraine specifically |
| [NCT05301387](https://clinicaltrials.gov/study/NCT05301387) | N/A | Completed | 38 | SPG block vs. placebo, but studies post-dural puncture headache (PDPH) rather than migraine — mechanistically related, not the same disease entity |
| [NCT06470581](https://clinicaltrials.gov/study/NCT06470581) | N/A | Not Yet Recruiting | 78 | Thoracic sympathetic ganglion block combined with Botulinum Toxin A for complex regional pain syndrome; combination design, cannot isolate ropivacaine's effect, and not yet recruiting |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Cohort | BMC Anesthesiology | Ultrasound-guided stellate ganglion block observed for migraine pain relief and quality-of-life improvement |
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Cohort | Pain Medicine | Ropivacaine trigger-point inactivation evaluated over 12 weeks for prophylactic management of severe migraine |
| [30043973](https://pubmed.ncbi.nlm.nih.gov/30043973/) | 2019 | Cohort | Headache | Sphenopalatine ganglion block evaluated for self-reported pain relief in status migrainosus |
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Case Series | Pain Physician | Describes a revised transnasal topical SPG block technique for headache and facial pain |
| [19145569](https://pubmed.ncbi.nlm.nih.gov/19145569/) | 2009 | Case Report | Revista de Neurología | Reports Horner's syndrome as a complication following epidural analgesia — an adverse event, not efficacy evidence |
| [17058040](https://pubmed.ncbi.nlm.nih.gov/17058040/) | 2006 | Case Report | The Journal of Headache and Pain | Reports migraine headache as a rare complication following cervicothoracic block |

---

## US Market Information

Ropivacaine currently has **no marketing authorizations on record** in the source dataset (0 licenses, market status: Not Marketed). No product/NDA table can be generated from the available evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

**Note:** Key warnings, contraindications, and drug-drug interaction data are currently unavailable (flagged as a **Blocking** data gap, DG001 — TFDA label warnings/contraindications not yet retrieved). This gap prevents the candidate from proceeding to the S1 safety initial assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The lead prediction (migraine disorder) sits at decision stage S2 with an internal recommendation of "Research Question," reflecting L2-level evidence that is procedural (nerve block techniques) rather than direct pharmacological repurposing evidence, and includes only one directly relevant RCT (n=10, underpowered). Combined with a **Blocking** safety data gap (DG001) that prevents any S1 safety assessment, and zero current marketing authorizations for ropivacaine in this dataset, the candidate is not ready to proceed even under guardrails.

**To proceed, the following is needed:**
- Retrieve TFDA/FDA package insert warnings and contraindications (DG001 — Blocking)
- Retrieve detailed mechanism of action data from DrugBank (DG002)
- Clarify route compatibility between ropivacaine's current approved routes and the nerve-block/regional injection routes used in the migraine evidence (route_compatibility currently "pending")
- Adequately powered RCT confirming SPG/stellate ganglion block efficacy for migraine (current Phase 4 RCT enrolled only 10 patients)
- Clarify current regulatory/market status given zero recorded licenses
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

